Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Theratechnologies Inc T.TH

Alternate Symbol(s):  THTX

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. It blocks viral entry into host cells while preserving normal immunologic function. The Company is also investigating an intramuscular method of administration of Trogarzo. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy.


TSX:TH - Post by User

Comment by jeffm34on Oct 23, 2021 10:14pm
184 Views
Post# 34041503

RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:New PR aroundVM

RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:New PR aroundVM

I guess the question is, how critical sortilin is to the formation of VM. Can VM occur in the absence of sortilin?  If not, then the applications for TH's cancer platform are staggering. 


JayjayUSA12007 wrote:
"Is it possible Theras PDC could be used as an adjunct to other chemo drugs that have reduced efficacy due to VM.  

https://scholar.google.ca/scholar?q=vascular+mimicry+effects+on+cancer+treatments&hl=en&as_sdt=0&as_vis=1&oi=scholart#d=gs_qabs&u=%23p%3DhYMFxg3j3CEJ "

Only when the neuroprotein sortilin are overexpressed on  cancerous tumors.
1/ Breast, lung, and thyroid cancers: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4496368/
2/ Pancreatic cancer: https://ascopost.com/news/august-2020/sortilin-may-be-a-potential-therapeutic-target-in-pancreatic-cancer/

If proven via clinical trials, TH1902 and TH1904 could become a anti-cancer platform. It won't take long before a big player will attempt to take out Thera, just to own this platform.
 



<< Previous
Bullboard Posts
Next >>

USER FEEDBACK SURVEY ×

Be the voice that helps shape the content on site!

At Stockhouse, we’re committed to delivering content that matters to you. Your insights are key in shaping our strategy. Take a few minutes to share your feedback and help influence what you see on our site!

The Market Online in partnership with Stockhouse